Nurix Therapeutics (NRIX) Stock Price, News & Analysis

+1.19 (+7.73%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
3.04 million shs
Average Volume
945,511 shs
Market Capitalization
$815.40 million
P/E Ratio
Dividend Yield
Price Target

Nurix Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
31.9% Upside
$21.88 Price Target
Short Interest
14.04% of Shares Sold Short
Dividend Strength
News Sentiment
0.23mentions of Nurix Therapeutics in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$85,756 Sold Last Quarter
Proj. Earnings Growth
From ($3.15) to ($3.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.01 out of 5 stars

Medical Sector

606th out of 922 stocks

Pharmaceutical Preparations Industry

282nd out of 425 stocks

NRIX stock logo

About Nurix Therapeutics Stock (NASDAQ:NRIX)

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

NRIX Stock Price History

NRIX Stock News Headlines

Key Takeaways From Nurix Therapeutics Analyst Ratings
Nurix Therapeutics Announces Proposed Public Offering
Nurix Therapeutics, Inc. Q1 Loss increases, but beats estimates
See More Headlines
Receive NRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$76.99 million
Book Value
$4.13 per share


Free Float
Market Cap
$815.40 million
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Arthur T. Sands M.D. (Age 62)
    Ph.D., CEO, President & Director
    Comp: $986.32k
  • Mr. Johannes Van Houte (Age 58)
    Chief Financial Officer
    Comp: $681.98k
  • Dr. Gwenn M. Hansen Ph.D. (Age 53)
    Chief Scientific Officer
    Comp: $702.75k
  • Dr. John Kuriyan Ph.D.
    Founder & Member of Scientific Advisory Board
  • Mr. Michael Rapé Ph.D.
    Founder & Member of Scientific Advisory Board
  • Dr. Arthur Weiss M.D.
    Ph.D., Founder & Member of Scientific Advisory Board
  • Rita Kwong
    Senior Accounting Manager
  • Dr. Christine Ring J.D. (Age 59)
    Ph.D., Chief Legal Officer, Secretary & Chief Compliance Officer
    Comp: $595.83k
  • Mr. Eric C. Schlezinger J.D. (Age 57)
    Chief People Officer
  • Dr. Jason Kantor Ph.D.
    Chief Business Officer

NRIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Nurix Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NRIX shares.
View NRIX analyst ratings
or view top-rated stocks.

What is Nurix Therapeutics' stock price target for 2024?

8 analysts have issued 12-month target prices for Nurix Therapeutics' stock. Their NRIX share price targets range from $10.00 to $31.00. On average, they expect the company's stock price to reach $21.88 in the next twelve months. This suggests a possible upside of 31.9% from the stock's current price.
View analysts price targets for NRIX
or view top-rated stocks among Wall Street analysts.

How have NRIX shares performed in 2024?

Nurix Therapeutics' stock was trading at $10.32 at the start of the year. Since then, NRIX shares have increased by 60.8% and is now trading at $16.59.
View the best growth stocks for 2024 here

When is Nurix Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024.
View our NRIX earnings forecast

How were Nurix Therapeutics' earnings last quarter?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced its earnings results on Wednesday, April, 10th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.04. The company earned $16.59 million during the quarter, compared to analysts' expectations of $14.58 million. Nurix Therapeutics had a negative trailing twelve-month return on equity of 67.08% and a negative net margin of 178.93%.

What ETFs hold Nurix Therapeutics' stock?
What other stocks do shareholders of Nurix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND), Delta Air Lines (DAL), DocuSign (DOCU), Fastly (FSLY) and Fiverr International (FVRR).

When did Nurix Therapeutics IPO?

Nurix Therapeutics (NRIX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager.

Who are Nurix Therapeutics' major shareholders?

Nurix Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (9.12%), Vanguard Group Inc. (5.26%), Price T Rowe Associates Inc. MD (4.47%), Wasatch Advisors LP (2.52%), Bain Capital Life Sciences Investors LLC (2.30%) and Affinity Asset Advisors LLC (1.65%). Insiders that own company stock include Christine Ring, Gwenn Hansen, Houte Hans Van, Pierre Beaurang and Stefani Wolff.
View institutional ownership trends

How do I buy shares of Nurix Therapeutics?

Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRIX) was last updated on 5/18/2024 by Staff

From Our Partners